top of page
Publications
2024
September 24
Commentary on: Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
Dahari, H., Cotler, SJ.
September 2024
Modeling challenges of hepatitis D virus kinetics during bulevirtide-based therapy
Mhlanga, A., et al.
March 2024
Reducing Sample Size While Improving Equity in Vaccine Clinical Trials: A Machine Learning-Based Recruitment Methodology with Application to Improving Trials of Hepatitis C Virus Vaccines in People Who Inject Drugs
February 2024
Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies
February 2024
Modelling HDV kinetics under entry-inhibitor Bulevirtide suggests the existence of two HDV-infected cell populations
2023
July 2023
Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kinetics
July 2023
Herpes Simplex Virus, Human Papillomavirus, and Cervical Cancer: Overview, Relationship, and Treatment Implications
June 2023
Hepatitis delta virus RNA decline post inoculation in human NTCP transgenic mice is biphasic
April 2023
Rapid monophasic hepatitis B surface antigen decline during nucleic-acid polymers-based therapy predicts functional cure
January 2023
Modeling-Based Response-Guided Hepatitis C Treatment during Pregnancy and Postpartum
2022
November 2022
Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring
Pathologies and Current Treatments
October 2022
Modeling the Interplay between HDV and HBV in Chronic HDV/HBV Patients
_PNG.webp)
June 2022
Advances in Parameter Estimation and Learning from Data for Mathematical Models of Hepatitis C Viral Kinetics
March 2022
Modeling hepatitis C micro-elimination among people who inject drugs with direct-acting antivirals in metropolitan Chicago
January 2022
Mathematical modeling suggests that entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation
January 2022
Machine learning for mathematical models of HCV kinetics during antiviral therapy
January 2022
A meta-analysis of 20 years of data on people who inject drugs in metropolitan Chicago to inform computational modeling
2021
_PNG.webp)
August 2021
A Mathematical Analysis of HDV Genotypes: From Molecules to Cells
_JPG.webp)
July 2021
Advances and Challenges in Managing Hepatitis D Virus: Evolving Strategies
April 2021
Understanding hepatitis B virus dynamics and the antiviral effect of interferon-a treatment in humanized chimeric mice
January 2021
Early HBV RNA kinetics under NA treatment may reveal new insights into HBV RNA dynamics and NA mode of action-more detailed kinetic studies are needed
January 2021
Understanding the antiviral effects of RNAi-based therapy on chronic hepatitis B infection
​
2020
June
Modeling based response guided therapy in subjects with recent hepatitis C infection
May
Evaluation of short-course direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A single-centre, open-label study
April
Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg
April
Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration
.webp)
April
Sustained Virological Response Following an 11 Day Course of Direct Acting Antiviral Therapy for Hepatitis C Infection
​
January
Modeling Challenges of Ebola Virus -Host Dynamics during Infection and Treatment​
2019
2018
February
High-Risk Geographic Mobility Patterns among Young Urban and Suburban Persons who Inject Drugs and their Injection Networks Members
Boodram B, et al.
2017
December
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients
Canini L et al.
October
A Robust and Efficient Numerical Method for RNA-Mediated Viral Dynamics
Reinharz V, et al.
August
Modeling HCV cure after an ultra-short duration of therapy with direct acting agents
Goyal A, et al.
June
Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection
Canini L, et al.
May
End of treatment RNA-positive/sustained viral response in an individual with acute HCV infection treated with direct-acting antivirals
Shtyer E, et al.
January
Prevalence of End of Treatment RNA-Positivity/Sustained Viral Response in HCV Patients Treated with Sofosbuvir Combination Therapies
Malespin M, et al.
2016
June
HCV Kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir
Dahari H, et al.
September
HCV dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy
DebRoy S, et al.
July
Hepatitis C virus cure after direct acting antiviral-related drug-induced liver injury: Case report
Hasin Y, et al.
.webp)
September
Resurrection of response-guided therapy for sofosbuvir combination therapies
Dahari H, et al.
2015
October
Oral Prenylation Inhibition with Lonafarnib in Chronic Hepatitis D Infection: a randomized, double-blinded, placebo controlled phase 2a trial
Koh C, et al.
September
Agent-based model forecasts aging of the population of people who inject drugs in metropolitan Chicago and changing prevalence of hepatitis C infections
Gutfraind A, et al.
August
Mathematical modeling of hepatitis C prevalence reduction with antiviral treatment scale-up in persons who inject drugs in metropolitan Chicago
Echevarria D, et al.
July
Quantification of HCV cell-to-cell spread using a stochastic modeling approach
Graw F, et al.
February
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modeling of HCV kinetics
Dahari H, et al.
January
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
Canini L, et al.
2014
December
Understanding early serum hepatitis D virus and HBsAg kinetics during pegylated interferon-alfa therapy via mathematical modeling
Guedj J, et al.
check
Treatment of hepatitis C with an interferon-based lead-in phase: A perspective from mathematical modeling
Rong L, et al.
January
Effect of Ribavirin on Viral Kinetics and Liver Gene Expression in Chronic Hepatitis C
Rotman Y, et al.
June
Individualized treatment for patients with low HCV load (genotype 1): A viral kinetic approach.
Dahari H, et al.
2013
March
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a new estimate of the hepatitis C virus half-life
check
April
Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection
Zhang J, et al.
March
Multiscale modeling approach predicts that the protease inhibitor danoprevir blocks several distinct stages of the HCV replication in vivo.
check
July
The HCV NS5A inhibitor daclatasvir has dual mode of action and reveals a shorter HCV half-life estimate.
Guedj J, et al.
January
Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
Canini L, et al.
2011
March
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a new estimate of the hepatitis C virus half-life
check
April
Modeling the acute and chronic phases of Theiler murine encephalomyelitis virus infection
Zhang J, et al.
March
Multiscale modeling approach predicts that the protease inhibitor danoprevir blocks several distinct stages of the HCV replication in vivo.
check
July
The HCV NS5A inhibitor daclatasvir has dual mode of action and reveals a shorter HCV half-life estimate.
Guedj J, et al.
2010
_edited.png)
May
Pharmacodynamics of PEG-IFN alpha-2a in HIV/HCV co-infected patients: Implications for treatment outcomes.
Dahari H, et al.
August
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density
Ali Sabahi, et al.
September
Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.
Neumann AU, et al.
2009
August
Mathematical modeling of viral kinetics under immune control during primary HIV-1 infection.
Burg D, et al.
.
Modeling HCV kinetics: The relationship between the infected cell loss rate and the final slope of viral decay.
Dahari H, et al.
April
A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease.
Dahari H, et al.
January
Modeling complex decay profiles of hepatitis B virus during antiviral therapy.
Dahari H, et al.
January
Analysis of hepatitis C virus infection models with hepatocyte homeostasis.
Reluga T​, et al.
2008
2007
July
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated Interferon and ribavirin.
Dahari H, et al
January
Mathematical modeling of subgenomic hepatitis C viral replication in Huh-7 cells.
Dahari H, et al
June
Hepatitis C virus RNA kinetics: Drug efficacy and the rate of HCV-infected cells loss.
Dahari H, Perelson AS, et al.
October
Hepatitis C virus kinetics in chimeric mice during antiviral therapy.
Dahari H, Perelson AS, et al.
2006
_edited.png)
_edited_edited.png)
2002
October
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.
Bouvier-Alias M, et al.
2000
July
Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.
Neumann AU, et al.
1998
July
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
Neumann AU, et al.
bottom of page